PD60-05 NEOADJUVANT CHEMOTHERAPY PLUS RADICAL CYSTECTOMY VERSUS RADICAL CYSTECTOMY ALONE IN CLINICAL T2 BLADDER CANCER PATIENTS WITHOUT HYDRONEPHROSIS: RESULTS FROM A LARGE MULTICENTER COHORT STUDY

Francesco Soria,Peter C. Black,Adrian Fairey,Michael S. Cookson,Evan Y. Yu,Wassim Kassouf,Marc A DallʼEra,Srikala S. Sridhar,John S. McGrath,Jonathan L. Wright,Andrew C. Thorpe,Todd M. Morgan,Jeffrey Holzbeierlein,Trinity J. Bivalacqua,Scott North,Daniel A. Barocas,Yair Lotan,Petros Grivas,Andrew J. Stephenson,Jay B. Shah,Bas W.G. van Rhijn,Philippe E. Spiess,Shahrokh F. Shariat,Paolo Gontero

PD60-05 NEOADJUVANT CHEMOTHERAPY PLUS RADICAL CYSTECTOMY VERSUS RADICAL CYSTECTOMY ALONE IN CLINICAL T2 BLADDER CANCER PATIENTS WITHOUT HYDRONEPHROSIS: RESULTS FROM A LARGE MULTICENTER COHORT STUDY

2020

INTRODUCTION AND OBJECTIVE:Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard and recommended treatment for clinical T2-T4aN0M0 bladder cancer. Howev...

Keywords:

Urology
Hydronephrosis
Cohort study
Medicine
Bladder cancer
Cystectomy
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations